This protocol covers hyperprolactinemia in the specific setting of a symptomatic prolactin-secreting pituitary microadenoma or macroadenoma — a clinically distinct population with defined management goals around prolactin control, tumor size, and gonadal function.
Patients with a symptomatic prolactin-secreting pituitary microadenoma or macroadenoma. The priority is lowering prolactin levels, reducing tumor burden, and restoring gonadal function.
The full evidence-based protocol for this scenario includes radiation therapy among the management options. The complete decision pathway — covering sequencing, selection criteria, and clinical decision points — is in the structured protocol.
DOI: 10.1210/jc.2010-1692
We recommend dopamine agonist therapy to lower prolactin levels, decrease tumor size, and restore gonadal function for patients harboring symptomatic prolactin-secreting microadenomas or macroadenomas.
For patients who fail surgical treatment or who harbor aggressive or malignant prolactinomas, we suggest radiation therapy.
View source ↗